OMAHA, Neb., Jan. 24 /PRNewswire-FirstCall/ -- Transgenomic, Inc. today announced that its Transgenomic Laboratories division has further strengthened their clinical diagnostic menu for mitochondrial disorders by adding ten nuclear gene screening assays. The ten autosomal genes encode key proteins for mitochondrial maintenance and function including: POLG1, DGUOK, TP, TK2, SURF1, SCO1, SCO2, COX10, BCS1L, and SLC25A4. It has been established that mutations in these genes are associated with various clinical disease syndromes that involve mitochondrial dysfunction. Early identification of these mutations can facilitate accurate diagnosis and improve patient care. The addition of these tests to the Transgenomic diagnostic services portfolio will expand Transgenomic Laboratories inherited disorder offering and broaden the genetic laboratory services available to clinical labs and pediatric neurologists. In making the announcement, Transgenomic's President and Chief Executive Officer, Craig Tuttle, stated, "The addition of the nuclear genes to the mitochondrial testing menu makes Transgenomic Laboratories one of the few molecular diagnostic labs in the country that can detect mitochondrial disease causing mutations in both the mitochondrial genome and the nuclear genome. This addition improves the service offering to our partner labs and should generate greater revenue. Transgenomic Laboratories delivers the most sensitive analysis across the broadest range of genes in the shortest period of time -- increasingly making Transgenomic the number one choice for mitochondrial genetic disorder analysis." Transgenomic Laboratories has unique proprietary expertise that enables the accurate detection of mutations with as low as 0.1% mutant to allele ratio making it one of the leading labs in the country for this type of testing methodology.
About Transgenomic: A decade of discovery 1997 - 2007
Transgenomic is a global biotechnology company that provides unique systems, products, discovery and laboratory testing services to the academic and medical research, clinical and pharmaceutical markets for automated high sensitivity genetic variation and mutation analysis in the fields of pharmacogenomics and personalized medicine. This is accomplished through their offerings of Wave(TM) DHPLC systems, reagents, consumables and assay kits, automated cytogenetics systems and Transgenomic Discovery and CLIA Lab Services. To date there have been over 1,200 Wave systems installed in over 600 customer sites in over 35 countries and approximately 1,500 publications utilizing Transgenomic products or services. Transgenomic Discovery and Lab Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: www.transgenomic.com.
Transgenomic Cautionary Statements
Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Transgenomic, Inc.CONTACT: Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,+1-402-452-5400, or fax, +1-402-452-5461,investorrelations@transgenomic.com
Web site: http://www.transgenomic.com/
